TY - JOUR
T1 - ABO blood group and risk of pancreatic carcinogenesis in intraductal papillary mucinous Neoplasms
AU - Hamada, Tsuyoshi
AU - Oyama, Hiroki
AU - Nakai, Yousuke
AU - Tada, Minoru
AU - Koh, Hideo
AU - Tateishi, Keisuke
AU - Arita, Junichi
AU - Hakuta, Ryunosuke
AU - Ijichi, Hideaki
AU - Ishigaki, Kazunaga
AU - Kawaguchi, Yoshikuni
AU - Kogure, Hirofumi
AU - Mizuno, Suguru
AU - Morikawa, Teppei
AU - Saito, Kei
AU - Saito, Tomotaka
AU - Sato, Tatsuya
AU - Takagi, Kaoru
AU - Takahara, Naminatsu
AU - Takahashi, Ryota
AU - Tanaka, Atsushi
AU - Tanaka, Mariko
AU - Ushiku, Tetsuo
AU - Hasegawa, Kiyoshi
AU - Koike, Kazuhiko
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Background: ABO blood group has been associated with risks of various malignancies, including pancreatic cancer. No study has evaluated the association of ABO blood group with incidence of pancreatic carcinogenesis during follow-up of patients with intraductal papillary mucinous neoplasms (IPMN). Methods: Among 3,164 patients diagnosed with pancreatic cysts at the University of Tokyo (Tokyo, Japan) from 1994 through 2019, we identified 1,815 patients with IPMN with available data on ABO blood group. We studied the association of ABO blood group with incidence of pancreatic carcinoma, overall and by carcinoma types [IPMN-derived carcinoma or concomitant pancreatic ductal adenocarcinoma (PDAC)]. Utilizing competing-risks proportional hazards models, we estimated subdistribution hazard ratios (SHR) for incidence of pancreatic carcinoma with adjustment for potential confounders, including cyst characteristics. Results: During 11,518 person-years of follow-up, we identified 97 patients diagnosed with pancreatic carcinoma (53 with IPMN-derived carcinoma and 44 with concomitant PDAC). Compared with patients with blood group O, patients with blood groups A, B, and AB had multivariable SHRs (95% confidence intervals) for pancreatic carcinoma of 2.25 (1.25–4.07; P ¼ 0.007), 2.09 (1.08–4.05; P ¼ 0.028), and 1.17 (0.43–3.19; P ¼ 0.76), respectively. We observed no differential association of ABO blood group with pancreatic carcinoma incidence by carcinoma types. Conclusions: In this large long-term study, patients with IPMN with blood group A or B appeared to be at higher risk of pancreatic carcinoma compared with those with blood group O. Impact: ABO blood group can be a biomarker for pancreatic cancer risk among patients with IPMNs.
AB - Background: ABO blood group has been associated with risks of various malignancies, including pancreatic cancer. No study has evaluated the association of ABO blood group with incidence of pancreatic carcinogenesis during follow-up of patients with intraductal papillary mucinous neoplasms (IPMN). Methods: Among 3,164 patients diagnosed with pancreatic cysts at the University of Tokyo (Tokyo, Japan) from 1994 through 2019, we identified 1,815 patients with IPMN with available data on ABO blood group. We studied the association of ABO blood group with incidence of pancreatic carcinoma, overall and by carcinoma types [IPMN-derived carcinoma or concomitant pancreatic ductal adenocarcinoma (PDAC)]. Utilizing competing-risks proportional hazards models, we estimated subdistribution hazard ratios (SHR) for incidence of pancreatic carcinoma with adjustment for potential confounders, including cyst characteristics. Results: During 11,518 person-years of follow-up, we identified 97 patients diagnosed with pancreatic carcinoma (53 with IPMN-derived carcinoma and 44 with concomitant PDAC). Compared with patients with blood group O, patients with blood groups A, B, and AB had multivariable SHRs (95% confidence intervals) for pancreatic carcinoma of 2.25 (1.25–4.07; P ¼ 0.007), 2.09 (1.08–4.05; P ¼ 0.028), and 1.17 (0.43–3.19; P ¼ 0.76), respectively. We observed no differential association of ABO blood group with pancreatic carcinoma incidence by carcinoma types. Conclusions: In this large long-term study, patients with IPMN with blood group A or B appeared to be at higher risk of pancreatic carcinoma compared with those with blood group O. Impact: ABO blood group can be a biomarker for pancreatic cancer risk among patients with IPMNs.
UR - http://www.scopus.com/inward/record.url?scp=85105447478&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-1581
DO - 10.1158/1055-9965.EPI-20-1581
M3 - Article
C2 - 33653811
AN - SCOPUS:85105447478
SN - 1055-9965
VL - 30
SP - 102
EP - 1028
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -
